Cell Therapy News

Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.

Subscribe|Follow Us On

Ex Vivo Live Macrophage Engineering Strategies in Immunotherapy

August 31, 2026

[Biotechnology Advances] Successful macrophage immunotherapy requires solving two central in vivo determinants: preserving a therapeutically favorable functional state despite suppressive cues, and achieving robust, disease-selective localization and engagement.

T Cell Immunosenescence Limits CD19 CAR T-Cell Function in Chronic Lymphocytic Leukemia

August 31, 2026

[Blood] Investigators identified immunosenescence as a measurable and functionally consequential barrier to CAR T-cell efficacy in chronic lymphocytic leukemia and a candidate for therapeutic modulation.

Tisa-Cel and Axi-Cel CAR Structure Influences the Development of Resistance to CD19-CAR-T Therapy

August 31, 2026

[Leukemia] Researcher showed that CAR structure is a critical determinant of CD19 loss in tumor B cells. Specifically, repeated exposure to CD19–4-1BB-based CAR-T cells, but not CD19–CD28-based counterparts, drives FMC63-epitope and total CD19 protein loss.

CD19 CAR T Cell Therapy for Treatment-Refractory Seropositive Rheumatoid Arthritis: A Phase I Trial

August 31, 2026

[Nature Medicine] Scientists reported clinical and molecular data obtained during the nonrandomized Phase I part of the Phase I/II COMPARE trial, evaluating safety and efficacy of mivocabtagene autoleucel (miv-cel), an autologous fully human CD19 CAR T cell therapy, in rheumatoid arthritis.

OHSU Researcher Awarded $4.2 Million to Advance Stem Cell Therapy for Age-Related Macular Degeneration

August 31, 2026

[OHSU ] Dr. Trevor McGill at Oregon Health & Science University (OHSU) has received a major federal grant to develop a new generation of stem cell therapies that could one day help preserve sight for those with the disease without requiring long-term immune-suppressing drugs.

C-Terminus CD28 Phosphorylation, Y218, Modulates IL-2 Secretion, and Therapeutic Effect of CAR-T Cells

August 31, 2026

[Molecular Therapy] The authors identified tyrosine 218 (Y218) in the CD28 cytoplasmic domain as a critical regulatory site, and demonstrate that its phosphorylation is essential for optimal CAR-T cell activity.

Targeting Regnase-1 in B7-H3-CAR T Cells Reprograms the Tumor Microenvironment and Enhances Antitumor Efficacy for Osteosarcoma

August 31, 2026

[Cell Reports Medicine] Investigators evaluated the intrinsic and extrinsic effects of deleting the negative regulator Regnase-1 in B7-H3-CAR T cells for the immunotherapy of osteosarcoma.

Expansion and CAR Engineering of Granulocyte-Monocyte Progenitors for Cellular Immunotherapy

August 31, 2026

[Cell] Researchers developed defined culture conditions that enable long-term expansion of mouse and human granulocyte-monocyte progenitors (GMPs) while preserving progenitor identity and myeloid potential, establishing GMPs as a renewable engineering platform.

New KWF Funding Boosts 8 CCA Cancer Research Projects

August 21, 2026

[Amsterdam UMC] KWF announced 34 research projects that will receive funding in its latest round — including 8 projects involving Cancer Center Amsterdam (CCA) researchers.

Engineered Macrophages with IL-10-TLR9 Signal Switch Receptors for Reprogramming Tumor Microenvironment and Enhancing Antitumor Immunity

August 17, 2026

[Experimental & Molecular Medicine] Investigators developed a CAR-like signal-switching receptor-macrophage that recognizes IL-10, a major immunosuppressive cytokine enriched in solid tumors, and converts this inhibitory signal into a pro-inflammatory activation through the Toll-like receptor 9 (TLR9) intracellular signaling pathway.

Stand Up To Cancer Announces Winner of Maverick Early Career Scientist Award

August 17, 2026

[Stand Up To Cancer] Stand Up To Cancer® as announced that Caitlin Zebley of St. Jude Children’s Research Hospital, is the recipient of the 2026 SU2C Maverick Early Career Scientist Award. The funding from the 2026 Maverick Award will support Dr. Zebley’s ongoing research focused on developing effective CAR T-cell therapies for children with acute myelogenous leukemia (AML).

CAR T Cell Therapy beyond Cancer: Current Status, Challenges, and Future Prospects

August 17, 2026

[Signal Transduction and Targeted Therapy] The authors highlight how CAR-based strategies can be adapted across diverse disease settings by redirecting engineered immune responses toward disease-sustaining cellular compartments.

Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.